Cobra Biologics and KAHR Medical extend partnership

Published: 27-Jun-2012

To develop treatment for cancer and autoimmune diseases

Cobra Biologics, a manufacturer of biologics and pharmaceuticals, has announced a continuation of its partnership with KAHR Medical, based in Jerusalem, Israel.

KAHR is a developer of novel drugs based on Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases.

The extended collaboration will allow Cobra Biologics to advance KAHR-101 and KAHR-102 for future pre-clinical and clinical testing using Cobra Biologics’ maxXpress service.

Cobra Biologics will also be carrying out the process development and scale-up for the GMP production of KAHR-101 and KAHR-102.

You may also like